Sustained release preparations
Patent 5399357 Issued on March 21, 1995. Estimated Expiration Date: 
March 21, 2012. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
March 21, 2012. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 3857933 Pharmaceutical composition of cyclandelate having a high degree of bioavailability Controlled-release dosage form comprising acetaminophen, pseudoephedrine and dexbrompheniramine Erodible matrix for sustained release bioactive composition Pharmaceutical composition comprising analgesic and anti-inflammatory agent Oral therapeutic system having systemic action Patent #: 4857336 InventorsAssigneeApplicationNo. 807630 filed on 12/13/1991US Classes:424/457, Sustained or differential release424/458, Containing discrete coated particles pellets, granules, or beads424/459, Organic coatings424/461, Containing polysaccharide (e.g., cellulose sugars, etc.)424/462, Containing solid synthetic polymers424/470, Where particles are granulated424/486, Synthetic polymer424/490, Coated (e.g., microcapsules)424/494, Cellulose derivatives424/495, Ethyl cellulose424/497, Containing solid synthetic polymers424/501, Contains solid synthetic resin514/785, Carboxylic acid ester514/951, POWDERS, GRANULES OR PARTICLES OF SPECIFIED MESH OR PARTICLE SIZE514/963, Microcapsule-sustained or differential release514/965Discrete particles in supporting matrixExaminersPrimary: Webman, Edward J.Attorney, Agent or FirmForeign Patent References
International ClassesA61K 009/16A61K 009/26 A61K 009/50 A61K 047/34 Foreign Application Priority Data1988-11-08 JPAbstractThere is provided a matrix preparation produced by dispersing a pharmaceutically active ingredient into a matrix which is solid at ambient temperature and comprised of a fatty acid ester of a polyglycerol. The preparation has stable release controlling ability, can be processed to fine granules, granules, capsules, tablets etc., and contributes to reduction of the administration times of the active ingredient and side effects of the ingredient.Other References
Field of SearchContaining discrete coated particles pellets, granules, or beadsWhere particles are granulated Synthetic polymer Contains solid synthetic resin Carboxylic acid ester Discrete particles in supporting matrix Microcapsule-sustained or differential release POWDERS, GRANULES OR PARTICLES OF SPECIFIED MESH OR PARTICLE SIZE | |
